Immunotherapy-based combinations in metastatic NSCLC.

Details

Ressource 1Download: 1-s2.0-S0305737223000361-main.pdf (1507.74 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_74C72B664E9F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunotherapy-based combinations in metastatic NSCLC.
Journal
Cancer treatment reviews
Author(s)
Desai A., Peters S.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Publication state
Published
Issued date
05/2023
Peer-reviewed
Oui
Volume
116
Pages
102545
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer (mNSCLC) since the approval of immunotherapy by the U.S. FDA in 2015. Despite the advancements, outcomes for patients have room for further improvement. Combination therapies have shown promise in overcoming resistance and improving outcomes. This review focuses on current immunotherapy-based combination approaches, reported and ongoing trials, as well as novel combination strategies, challenges, and future directions for mNSCLC treatment. We summarize approaches in combination with chemotherapy, novel immune checkpoints, tyrosine kinase inhibitors and other strategies including vaccines, and radiation therapy. The promise of biomarker-driven studies to understand resistance and design multi-arm platform trials that evaluate novel therapies is becoming of increasing relevance with the ultimate goal of administering precision immunotherapy by identifying the right dose of the right combination for the right patient at the right time.
Keywords
Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Immunotherapy, Combined Modality Therapy, Immune checkpoints, Metastatic, NSCLC, Non-small cell lung cancer
Pubmed
Web of science
Open Access
Yes
Create date
17/04/2023 10:59
Last modification date
09/12/2023 8:13
Usage data